Houston Clinical Trials

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: IV

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: IV

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: PHIII IGRT/SBRTvsIGRT/HypoIMRT IntProst View

Description: Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005)

Indication: Prostate Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Pembrolizumab NMIBC Ref/Intol to BCG View

Description: A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy (MK-3475 057)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Ph 3 Pembro Neoadj TNBC View

Description: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: Ph2 DS-8201a HER2+ unresect/mBC View

Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: I/II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Enzal +/- PI3 Kinase/mTOR inhib mCRPC View

Description: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study ofEnzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414in Men with Metastatic Castration Resistant Prostate Cancer (GU 115/I6A-MC-CBBD)

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Ph3 Ipatasertib+Abi+Pred mCRPC View

Description: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS (PTEN DIAGNOSTIC POSITIVE) TUMORS - Roche CO39303

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: Ph3 Pembro RCC post nephrectomy View

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Indication: Renal Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Houston Southeast

Phase: IV

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Houston Southeast

Phase: II

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: PHIII IGRT/SBRTvsIGRT/HypoIMRT IntProst View

Description: Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005)

Indication: Prostate Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Sugar Land

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Sugar Land

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Sugar Land

Phase: IV

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Sugar Land

Phase: II

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Sugar Land

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Sugar Land

Phase: III

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Ph2 Atezol +/- Entinostat adv TNBC View

Description: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients with Advanced Triple Negative Breast Cancer, with a Phase 1b Lead in Phase (SNDX-275-0602)

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-The Woodlands

Phase: IV

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-The Woodlands

Phase: II

Title: Ph2 NUC-1031 Pt-Resist Ovarian View

Description: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105)

Indication: Ovarian Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: II

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: IV

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Title: Ph 1b2 LIV1A+Pembro 1L mTNBC View

Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Pembrolizumab NMIBC Ref/Intol to BCG View

Description: A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy (MK-3475 057)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Bladder Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Ph2 Atezol +/- Entinostat adv TNBC View

Description: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients with Advanced Triple Negative Breast Cancer, with a Phase 1b Lead in Phase (SNDX-275-0602)

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Ph2 DS-8201a HER2+ unresect/mBC View

Description: DS8201-A-U201: A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201a, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: Cypress 1: Ph 2 AM0010+Pembro NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression (AM0010-201)

Indication: Lung Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: Cypress 2: Ph2 AM0010+Nivo NSCLC View

Description: A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)

Indication: Lung Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-The Woodlands

Phase: II

Title: Ph2 NUC-1031 Pt-Resist Ovarian View

Description: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105)

Indication: Ovarian Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Enzal +/- PI3 Kinase/mTOR inhib mCRPC View

Description: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study ofEnzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414in Men with Metastatic Castration Resistant Prostate Cancer (GU 115/I6A-MC-CBBD)

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: Sitravatinib + Nivo Adv/Met Urothelial View

Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Sugar Land

Phase: III

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Sugar Land

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: Ph 3 Pembro Neoadj TNBC View

Description: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: Ph3 SYD985 HER2+ unresect adv/mBC View

Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Indication: Breast Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Ph3b 1L CLL debulk combo View

Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

Indication: Leukemia

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: FOLFOX +/1 AM0010 Panc View

Description: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Sugar Land

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: Ph3 Ipatasertib+Abi+Pred mCRPC View

Description: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WITH PTEN-LOSS (PTEN DIAGNOSTIC POSITIVE) TUMORS - Roche CO39303

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Sugar Land

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: PHIII IGRT/SBRTvsIGRT/HypoIMRT IntProst View

Description: Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005)

Indication: Prostate Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: III

Title: PHIII IGRT/SBRTvsIGRT/HypoIMRT IntProst View

Description: Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005)

Indication: Prostate Cancer

Location: Texas Oncology-Houston Southeast

Phase: III

Title: Ph3 Pembro RCC post nephrectomy View

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Indication: Renal Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Hematologic

Location: Texas Oncology-The Woodlands

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Sugar Land

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Houston Southeast

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: IV

Title: Molecular Markers - Malignant Tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: IV